169 related articles for article (PubMed ID: 29025245)
1. Hepatic chemerin mRNA in morbidly obese patients with nonalcoholic fatty liver disease.
Kajor M; Kukla M; Waluga M; Liszka Ł; Dyaczyński M; Kowalski G; Żądło D; Berdowska A; Chapuła M; Kostrząb-Zdebel A; Bułdak RJ; Sawczyn T; Hartleb M
Pol J Pathol; 2017; 68(2):117-127. PubMed ID: 29025245
[TBL] [Abstract][Full Text] [Related]
2. Vaspin mRNA levels in the liver of morbidly obese women with nonalcoholic fatty liver disease.
Waluga M; Kukla M; Żorniak M; Grabiec M; Kajor M; Dyaczyński M; Kowalski G; Żądło D; Berdowska A; Kotulski R; Bułdak RJ; Sawczyn T; Waluga E; Olczyk P; Hartleb M
Pol J Pathol; 2017; 68(2):128-137. PubMed ID: 29025246
[TBL] [Abstract][Full Text] [Related]
3. Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease.
Döcke S; Lock JF; Birkenfeld AL; Hoppe S; Lieske S; Rieger A; Raschzok N; Sauer IM; Florian S; Osterhoff MA; Heller R; Herrmann K; Lindenmüller S; Horn P; Bauer M; Weickert MO; Neuhaus P; Stockmann M; Möhlig M; Pfeiffer AF; von Loeffelholz C
Eur J Endocrinol; 2013 Nov; 169(5):547-57. PubMed ID: 23935128
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor-21 and omentin-1 hepatic mRNA expression and serum levels in morbidly obese women with non-alcoholic fatty liver disease.
Waluga M; Kukla M; Zorniak M; Kajor M; Liszka L; Dyaczynski M; Kowalski G; Zadlo D; Waluga E; Olczyk P; Buldak RJ; Berdowska A; Hartleb M
J Physiol Pharmacol; 2017 Jun; 68(3):363-374. PubMed ID: 28820393
[TBL] [Abstract][Full Text] [Related]
5. Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis.
Pohl R; Haberl EM; Rein-Fischboeck L; Zimny S; Neumann M; Aslanidis C; Schacherer D; Krautbauer S; Eisinger K; Weiss TS; Buechler C
Eur J Clin Invest; 2017 Jan; 47(1):7-18. PubMed ID: 27797398
[TBL] [Abstract][Full Text] [Related]
6. Hepatic chemerin and chemokine-like receptor 1 expression in patients with chronic hepatitis C.
Kukla M; Adamek B; Waluga M; Zalewska-Ziob M; Kasperczyk J; Gabriel A; Mazur W; Sobala-Szczygieł B; Bułdak RJ; Zajęcki W; Kępa L; Ziora K; Żwirska-Korczala K; Wiczkowski A; Hartleb M
Biomed Res Int; 2014; 2014():517820. PubMed ID: 25121101
[TBL] [Abstract][Full Text] [Related]
7. Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity.
Bekaert M; Ouwens DM; Hörbelt T; Van de Velde F; Fahlbusch P; Herzfeld de Wiza D; Van Nieuwenhove Y; Calders P; Praet M; Hoorens A; Geerts A; Verhelst X; Kaufman JM; Lapauw B
Obesity (Silver Spring); 2016 Dec; 24(12):2544-2552. PubMed ID: 27768254
[TBL] [Abstract][Full Text] [Related]
8. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
9. Chemerin in a Mouse Model of Non-alcoholic Steatohepatitis and Hepatocarcinogenesis.
Haberl EM; Pohl R; Rein-Fischboeck L; Feder S; Sinal CJ; Buechler C
Anticancer Res; 2018 May; 38(5):2649-2657. PubMed ID: 29715085
[TBL] [Abstract][Full Text] [Related]
10. Chemerin/CMKLR1 ameliorates nonalcoholic steatohepatitis by promoting autophagy and alleviating oxidative stress through the JAK2-STAT3 pathway.
An X; Liu J; Li Y; Dou Z; Li N; Suo Y; Ma Y; Sun M; Tian Z; Xu L
Peptides; 2021 Jan; 135():170422. PubMed ID: 33144092
[TBL] [Abstract][Full Text] [Related]
11. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery.
Sell H; Divoux A; Poitou C; Basdevant A; Bouillot JL; Bedossa P; Tordjman J; Eckel J; Clément K
J Clin Endocrinol Metab; 2010 Jun; 95(6):2892-6. PubMed ID: 20375212
[TBL] [Abstract][Full Text] [Related]
12. SFRP5 hepatic expression is associated with non-alcoholic liver disease in morbidly obese women.
Gutiérrez-Vidal R; Vega-Badillo J; Reyes-Fermín LM; Hernández-Pérez HA; Sánchez-Muñoz F; López-Álvarez GS; Larrieta-Carrasco E; Fernández-Silva I; Méndez-Sánchez N; Tovar AR; Villamil-Ramírez H; Mejía-Domínguez AM; Villarreal-Molina T; Hernández-Pando R; Campos-Pérez F; Aguilar-Salinas CA; Canizales-Quinteros S
Ann Hepatol; 2015; 14(5):666-74. PubMed ID: 26256895
[TBL] [Abstract][Full Text] [Related]
13. Chemerin is highly expressed in hepatocytes and is induced in non-alcoholic steatohepatitis liver.
Krautbauer S; Wanninger J; Eisinger K; Hader Y; Beck M; Kopp A; Schmid A; Weiss TS; Dorn C; Buechler C
Exp Mol Pathol; 2013 Oct; 95(2):199-205. PubMed ID: 23906870
[TBL] [Abstract][Full Text] [Related]
14. [The expression of chemerin and the influence of sitagliptin on its expression in non-alcoholic fatty liver disease rats complicated with prediabetes].
Zhang L; Gao XF; Wang YH
Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(30):2407-2413. PubMed ID: 30138985
[No Abstract] [Full Text] [Related]
15. Irisin in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
[TBL] [Abstract][Full Text] [Related]
16. Serum chemerin and vaspin in non-alcoholic fatty liver disease.
Kukla M; Zwirska-Korczala K; Hartleb M; Waluga M; Chwist A; Kajor M; Ciupinska-Kajor M; Berdowska A; Wozniak-Grygiel E; Buldak R
Scand J Gastroenterol; 2010; 45(2):235-42. PubMed ID: 20095887
[TBL] [Abstract][Full Text] [Related]
17. Chemokine-Like Receptor 1 mRNA Weakly Correlates with Non-Alcoholic Steatohepatitis Score in Male but Not Female Individuals.
Neumann M; Meier EM; Rein-Fischboeck L; Krautbauer S; Eisinger K; Aslanidis C; Pohl R; Weiss TS; Buechler C
Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27548138
[TBL] [Abstract][Full Text] [Related]
18. Deregulation of Secreted Frizzled-Related Protein 5 in Nonalcoholic Fatty Liver Disease Associated with Obesity.
Bertran L; Portillo-Carrasquer M; Aguilar C; Porras JA; Riesco D; Martínez S; Vives M; Sabench F; Gonzalez E; Del Castillo D; Richart C; Auguet T
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34198988
[TBL] [Abstract][Full Text] [Related]
19. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis.
Hohenester S; Christiansen S; Nagel J; Wimmer R; Artmann R; Denk G; Bischoff M; Bischoff G; Rust C
Am J Physiol Gastrointest Liver Physiol; 2018 Sep; 315(3):G329-G338. PubMed ID: 29878845
[TBL] [Abstract][Full Text] [Related]
20. Chemokine-like receptor 1 deficiency does not affect the development of insulin resistance and nonalcoholic fatty liver disease in mice.
Gruben N; Aparicio Vergara M; Kloosterhuis NJ; van der Molen H; Stoelwinder S; Youssef S; de Bruin A; Delsing DJ; Kuivenhoven JA; van de Sluis B; Hofker MH; Koonen DP
PLoS One; 2014; 9(4):e96345. PubMed ID: 24781986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
